155 related articles for article (PubMed ID: 34364187)
1. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries.
Wenzel M; Collà Ruvolo C; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Mandel P; Chun FKH; Karakiewicz PI
Cancer Epidemiol; 2021 Oct; 74():101994. PubMed ID: 34364187
[TBL] [Abstract][Full Text] [Related]
2. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
3. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
J Urol; 2021 Jul; 206(1):69-79. PubMed ID: 33683934
[TBL] [Abstract][Full Text] [Related]
4. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
[TBL] [Abstract][Full Text] [Related]
5. Improving the stratification of intermediate risk prostate cancer.
Nocera L; Collà Ruvolo C; Stolzenbach LF; Deuker M; Tian Z; Gandaglia G; Fossati N; Abdollah F; Suardi N; Mirone V; Graefen M; Chun FK; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Minerva Urol Nephrol; 2022 Oct; 74(5):590-598. PubMed ID: 33887893
[TBL] [Abstract][Full Text] [Related]
6. Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Mori K; Tian Z; Shariat SF; Saad F; Briganti A; Suardi N; Terrone C; Gallucci M; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
Prostate; 2021 Aug; 81(11):778-784. PubMed ID: 34057220
[TBL] [Abstract][Full Text] [Related]
7. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
8. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
9. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
10. Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Clin Genitourin Cancer; 2021 Aug; 19(4):e255-e263. PubMed ID: 33849813
[TBL] [Abstract][Full Text] [Related]
11. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
Pompe RS; Smith A; Bandini M; Marchioni M; Martel T; Preisser F; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Shariat SF; Tilki D; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):71-77. PubMed ID: 29339806
[TBL] [Abstract][Full Text] [Related]
12. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
[TBL] [Abstract][Full Text] [Related]
13. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
14. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
[TBL] [Abstract][Full Text] [Related]
15. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
16. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
17. Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
Würnschimmel C; Kachanov M; Wenzel M; Mandel P; Karakiewicz PI; Maurer T; Steuber T; Tilki D; Graefen M; Budäus L
Prostate; 2021 Sep; 81(12):849-856. PubMed ID: 34110033
[TBL] [Abstract][Full Text] [Related]
18. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
[TBL] [Abstract][Full Text] [Related]
19. Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy.
Boehm K; Tennstedt P; Beyer B; Schiffmann J; Beckmann A; Michl U; Beyersdorff D; Budäus L; Graefen M; Karakiewicz PI; Salomon G
World J Urol; 2016 Jun; 34(6):805-10. PubMed ID: 26481227
[TBL] [Abstract][Full Text] [Related]
20. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]